Quanterix Corp(QTRX) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 29 at 4:00 PM ET (Korea 10/30 05:00)
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -2.63 | Insider Own | 11.73% | Shs Outstand | 47.1M | Perf Week | 10.74% |
| Market Cap | 0.15B | Forward P/E | - | EPS next Y | 44.8% | Insider Trans | 1.89% | Shs Float | 41.8M | Perf Month | -15.23% |
| Enterprise Value | 0.09B | PEG | - | EPS next Q | -0.42 | Inst Own | 62.37% | Short Float | 11.21% | Perf Quarter | -9.63% |
| Income | -0.12B | P/S | 0.97 | EPS this Y | 10.76% | Inst Trans | -16.31% | Short Ratio | 6.26 | Perf Half Y | 0.48% |
| Sales | 0.15B | P/B | 0.62 | EPS next 5Y | 25.85% | ROA | -35.42% | Short Interest | 4.68M | Perf YTD | -50.55% |
| Book/sh | 5.03 | P/C | 1.59 | EPS past 3/5Y | 2.27% -18.72% | ROE | -46.49% | 52W High | -64.14% ($8.77) | Perf Year | -39.17% |
| Cash/sh | 1.98 | P/FCF | - | Sales past 3/5Y | 9.59% 9.97% | ROIC | -46.85% | 52W Low | 46.28% ($2.15) | Perf 3Y | -84.66% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -44.65% | Gross Margin | 42.69% | Volatility(W/M) | 5.72% 7.28% | Perf 5Y | -93.79% |
| Dividend TTM | - | EV/Sales | 0.58 | Sales Y/Y TTM | 21.96% | Oper. Margin | -63.91% | ATR (14) | 0.21 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 2.45 | EPS Q/Q | -34.44% | Profit Margin | -80.25% | RSI (14) | 53.78 | Recom | 3 |
| Dividend Gr. 3/5Y | - | Current Ratio | 3.4 | Sales Q/Q | 34.44% | SMA20 | 1.48% ($3.09) | Beta | 1.02 | Target Price | $3.17 |
| Payout | - | Debt/Eq | 0.14 | Earnings | 2026/11/9 | SMA50 | 5.11% ($2.99) | Rel Volume | 0.45 | Prev Close | $3.12 |
| Employees | 450 | LT Debt/Eq | 0.11 | EPS/Sales Surpr. | -153.47% -12.2% | SMA200 | -19.17% ($3.88) | Avg Volume(3M) | 0.75M | Price | $3.14 |
| IPO | 2017/12/7 | Option/Short | Yes/Yes | Trades | 2948 | Volume | 334,197 | Change | 0.8% |
🧬 A medical device and life sciences company developing an ultra-sensitive protein biomarker detection platform. Leveraging Simoa technology, the company targets the precision diagnostics and research markets in neurology, oncology, and immunology, and has recently expanded its business into spatial biology.
Over the past 1 year, on the lower side
64% below its 1-year high.
Traded less than usual. That is 45% of its average volume.
Next earnings report: November 9
10 days to go.
QTRX has a sound balance sheet but weak earning power
Of every $100 in sales, $63.91 is lost.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +10.8% this year.
Tap to view numbers
Relative to sales, the price is about the industry average
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $97. Peers typically go for $154.
Tap to view numbers
Results came in about as expected
Mixed beats and misses
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Hold.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -93.8%. The S&P 500 did +68% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 62.4%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #81 of 142 in the industry
Based on market cap of $149M.
MXCT#80 MaxCyte Inc $179M PER - QTRX#81 Quanterix Corp $149M PER - 
LUNG#82 Pulmonx Corp $136M PER - 
CATX#83 Perspective Therapeutics Inc $134M PER - 
OWLT#84 Owlet Inc $122M PER - 
FAQ
What kind of company is QTRX?
QTRX belongs to the Healthcare sector and operates in the Medical Devices industry.
What is the market cap of QTRX?
The market cap of QTRX is approximately $149M, ranking 4,242 within its sector.
What is the 52-week high and low for QTRX?
QTRX has recorded a 52-week high of $8.77 and a low of $2.15.
